Paci­ra looks to ex­pand use of Ex­par­el for pain re­lief fol­low­ing knee re­place­ment surgery

Paci­ra Bio­sciences is hop­ing that the lat­est da­ta sur­round­ing its non-opi­oid painkiller will ex­pand its us­age post-surgery.

On Wednes­day, the biotech pre­sent­ed topline re­sults from a Phase III study in­ves­ti­gat­ing its bupi­va­caine-based treat­ment Ex­par­el for post-sur­gi­cal use in pa­tients un­der­go­ing a to­tal knee re­place­ment.

The com­pa­ny re­port­ed that its tri­al hit its pri­ma­ry end­point show­ing a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in cu­mu­la­tive pain scores from ze­ro to 96 hours com­pared with a com­mon bupi­va­caine-HCl in­jec­tion, reach­ing a p-val­ue of p=<0.01.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER